All Stories

  1. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2018, Dove Medical Press

    Peter Calverley, Achim Mueller, Robert Wise

  2. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2017, Dove Medical Press

    Peter Calverley, Achim Mueller, Kay Tetzlaff, Robert Wise

  3. Effect of a single exacerbation on decline in lung function in COPD

    Article • Respiratory Medicine, July 2017, Elsevier

    Achim Mueller

  4. Assessing COPD profiles and outcomes by dyspnoea severity

    Article • Pneumologie, February 2017, Thieme Publishing Group

    Achim Mueller

  5. How investigators differ in determining cause of death for COPD patients

    Article • ERJ Open Research, January 2017, European Respiratory Society (ERS)

    Achim Mueller, Robert Wise

  6. Tiotropium in chronic obstructive pulmonary disease: Gender differences in outcomes

    Article • September 2016, European Respiratory Society (ERS)

    Achim Mueller

  7. Secondary analysis of the UPLIFT® trial by body mass index

    Article • September 2016, European Respiratory Society (ERS)

    Achim Mueller

  8. Assessing COPD profiles and outcomes by dyspnoea severity

    Article • September 2016, European Respiratory Society (ERS)

    Achim Mueller

  9. Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR®post-hocanalysis

    Article • September 2016, European Respiratory Society (ERS)

    Achim Mueller

  10. Rate of FEV1decline by FEV1percent predicted in UPLIFT® and TIOSPIR®

    Article • September 2016, European Respiratory Society (ERS)

    Achim Mueller

  11. Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in China Versus Rest of the World

    Article • CHEST Journal, April 2016, Elsevier

    Achim Mueller

  12. Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in Asia Countries (Excluding China) Versus Rest of the World

    Article • CHEST Journal, April 2016, Elsevier

    Achim Mueller

  13. T Safety And Performance In Respimat® (TIOSPIR™): Safety And Efficacy In Patients With T HH® Use At Baseline

    Article • Pneumologie, February 2016, Thieme Publishing Group

    Achim Mueller

  14. Impact des antécédents d’exacerbations et de l’utilisation des CSI sur le devenir des patients BPCO de l’étude TIOSPIR™

    Article • Revue des Maladies Respiratoires, January 2016, Elsevier

    Achim Mueller

  15. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial

    Article • BMJ Open, December 2015, BMJ

    Achim Mueller

  16. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial

    Article • npj Primary Care Respiratory Medicine, November 2015, Nature

    Achim Mueller

  17. Investigator-reported vs adjudicated cause of death in the TIOSPIR™ trial

    Article • September 2015, European Respiratory Society (ERS)

    Achim Mueller

  18. Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial

    Article • September 2015, European Respiratory Society (ERS)

    Achim Mueller

  19. LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels

    Article • September 2015, European Respiratory Society (ERS)

    Achim Mueller

  20. Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial

    Article • September 2015, European Respiratory Society (ERS)

    Achim Mueller

  21. Safety of tiotropium in patients with cardiac events in the UPLIFT® trial

    Article • September 2015, European Respiratory Society (ERS)

    Achim Mueller

  22. Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2015, Taylor & Francis

    Achim Mueller

  23. TIOSPIR : caractéristiques de patients avec exacerbations

    Article • Revue des Maladies Respiratoires, January 2015, Elsevier

    Achim Mueller

  24. P262 Tiotropium Safety And Performance In Respimat(R) (tiospir ): Safety And Efficacy In Patients With Tiotropium Handihaler(R) Use At Baseline

    Article • Thorax, November 2014, BMJ

    Achim Mueller

  25. P261 Tiotropium Safety And Performance In Respimat(R) (tiospir ): Safety And Efficacy In Patients Naive To Treatment With Anticholinergics

    Article • Thorax, November 2014, BMJ

    Achim Mueller